Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy
City Of Hope National Medical Center · City of Hope · +2 more institutions
Abstract
Chimeric antigen receptor (CAR) T-cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR T manufacturing remains costly, individualized, and logistically complex, posing significant barriers to accessibility and scalability. In vivo CAR T-cell engineering offers a transformative alternative by reprogramming endogenous T cells within the patient, bypassing the need for cell harvesting and expansion. This review focuses on current in vivo CAR T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles) and nonviral systems (such…
Citation impact
- FWCI
- 60.64
- Percentile
- 100%
- References
- 0
Authors
4- RWRuiheng WangCorresponding
City Of Hope National Medical Center, City of Hope
- JYJianhua Yu
University of California, Irvine, Precision Therapeutics (United States)
- MAM. A. Caligiuri
City Of Hope National Medical Center, City of Hope
- SMShoubao Ma
City Of Hope National Medical Center, City of Hope
Topics & keywords
- Chimeric antigen receptor
- Immunogenicity
- In vivo
- Immunotherapy
- Cancer immunotherapy
- Ex vivo
- Immune system
- Cell therapy